ICU REACH

11/15/2025

Systemic corticosteroids are recommended for severe CAP based on trials like CAPE-COD and supporting meta-analyses. However, the REMAP-CAP trial found no mortality benefit—and possible harm—from hydrocortisone, raising concerns. Despite this, a Bayesian meta-analysis still supports corticosteroid use in high-risk ICU patients. Clinical decisions should consider disease severity, etiology, and individual patient factors.

11/12/2025

Explore the findings of the BALANCE Trial: a pivotal study examining the efficacy of 7 days versus 14 days of antibiotics for bloodstream infections. This research shows that shorter therapy is not only effective but also supports antimicrobial stewardship. Dive deeper here: https://wix.to/HrgwcfF

11/10/2025

We uncover the latest findings from the BICARICU-2 trial. Learn how intravenous sodium bicarbonate impacts patients facing severe metabolic acidemia and acute kidney injury. This study illuminates fresh perspectives on renal care. Join the discussion! https://wix.to/sgPHVyz

In patients with severe metabolic acidemia and moderate to severe acute kidney injury, intravenous sodium bicarbonate did not reduce mortality but was associated with a lower rate and delayed initiation of renal replacement therapy.

11/06/2025

A groundbreaking study in the NEJM suggests that many patients in shock might not need early arterial catheterization. Could this change standard ICU practices? Check out the full article to share your thoughts! https://wix.to/jTc3nVm

03/09/2025

ICU REACH Newsletter (March 9, 2025) https://wix.to/gx1XIbC

12/30/2024

ICU REACH Newsletter (December 30, 2024) https://wix.to/39huR5M

12/12/2024

ICU REACH Newsletter (December 12, 2024) https://wix.to/xOfa9L7

12/02/2024

Breath by Breath: Educational Videos on Ventilator Mastery https://wix.to/NfcapsF

11/20/2024

Breath by Breath: Educational Videos on Ventilator Mastery https://wix.to/f9mudEO

11/20/2024

PEERLESS Trial in Pulmonary Embolism https://wix.to/5D9d01Q

11/19/2024

The PEERLESS trial provides compelling evidence that LBMT offers an effective and safe alternative to CDT for intermediate-risk PE patients, with benefits in ICU utilization, lower clinical deterioration rates, and shorter hospital stays. https://wix.to/45rtqXN

11/19/2024

https://youtu.be/Gp918RXVGhI?feature=shared

[LBMT] and catheter-directed thrombolysis (CDT) in managing intermediate-risk pulmonary embolism (PE). Enrolling 550 patients, the study assessed a primary c...